These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12161479)

  • 21. Selective embolization of thyroid arteries (SETA) as a palliative treatment of inoperable anaplastic thyroid carcinoma (ATC).
    Tazbir J; Dedecjus M; Kaurzel Z; Lewiński A; Brzeziński J
    Neuro Endocrinol Lett; 2005 Aug; 26(4):401-6. PubMed ID: 16136001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The efficacy of thyroidectomy for Graves' disease: A meta-analysis.
    Palit TK; Miller CC; Miltenburg DM
    J Surg Res; 2000 May; 90(2):161-5. PubMed ID: 10792958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study.
    Howarth D; Epstein M; Lan L; Tan P; Booker J
    Eur J Nucl Med; 2001 Oct; 28(10):1489-95. PubMed ID: 11685491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The outcome of 131I treatment in Graves' patients pretreated or not with methimazole.
    Pirnat E; Zaletel K; Gaberšček S; Hojker S
    Hell J Nucl Med; 2011; 14(1):25-9. PubMed ID: 21512661
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
    Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diffusion-weighed MR of the thyroid gland in Graves' disease: assessment of disease activity and prediction of outcome.
    Abdel Razek AA; Sadek AG; Gaballa G
    Acad Radiol; 2010 Jun; 17(6):779-83. PubMed ID: 20350826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H; Hirota Y; Kasagi K; Matsubayashi S; Kuma K; Iida Y; Konishi J; Okimura MC; Walter RM; Kumagai LF
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exacerbation of thyroid associated ophthalmopathy after arterial embolization therapy in a patient with Graves' disease.
    Hiraiwa T; Imagawa A; Yamamoto K; Arimoto H; Arishima T; Ito M; Nakamura Y; Matsuzuka F; Miyauchi A; Sugasawa J; Ikeda T; Narumi Y; Hanafusa T
    Endocrine; 2009 Jun; 35(3):302-5. PubMed ID: 19381887
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose.
    Haase A; Bähre M; Lauer I; Meller B; Richter E
    Exp Clin Endocrinol Diabetes; 2000; 108(2):133-7. PubMed ID: 10826521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pituitary-thyroid regulation in euthyroid patients with Graves' disease previously treated with antithyroid drugs.
    Buerklin EM; Schimmel M; Utiger RD
    J Clin Endocrinol Metab; 1976 Aug; 43(2):419-27. PubMed ID: 59733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.
    Murakami Y; Takamatsu J; Sakane S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3257-60. PubMed ID: 8784079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
    Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
    Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine.
    Ward L; Huot C; Lambert R; Deal C; Collu R; Van Vliet G
    Clin Invest Med; 1999 Aug; 22(4):132-9. PubMed ID: 10497711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epithelial hyperplasia and decreased colloid content of the thyroid gland in triiodothyronine-predominant Graves' disease.
    Takamatsu J; Takeda K; Katayama S; Sakane S; Morita S; Kuma K; Ohsawa N
    J Clin Endocrinol Metab; 1992 Oct; 75(4):1145-50. PubMed ID: 1400885
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves' disease.
    Moura-Neto A; Mosci C; Santos AO; Amorim BJ; de Lima MC; Etchebehere EC; Tambascia MA; Ramos CD; Zantut-Wittmann DE
    Clin Nucl Med; 2012 Jun; 37(6):550-4. PubMed ID: 22614185
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group.
    Tallstedt L; Lundell G; Tørring O; Wallin G; Ljunggren JG; Blomgren H; Taube A
    N Engl J Med; 1992 Jun; 326(26):1733-8. PubMed ID: 1489388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
    Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
    Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does thyroidectomy, radioactive iodine therapy, or antithyroid drug treatment alter reactivity of patients' T cells to epitopes of thyrotropin receptor in autoimmune thyroid diseases?
    Soliman M; Kaplan E; Abdel-Latif A; Scherberg N; DeGroot LJ
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2312-21. PubMed ID: 7543112
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apoptotic study in Graves disease treated with thyroid arterial embolization.
    Zhao W; Gao BL; Yi GF; Jin CZ; Yang HY; Shen LJ; Tian M; Yu YZ; Li H; Song DP
    Endocr J; 2009; 56(2):201-11. PubMed ID: 19008632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.
    Romaldini JH; Bromberg N; Werner RS; Tanaka LM; Rodrigues HF; Werner MC; Farah CS; Reis LC
    J Clin Endocrinol Metab; 1983 Sep; 57(3):563-70. PubMed ID: 6192139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.